Xenetic Biosciences Inc
$ 3.17
11.23%
07 Aug - close price
- Market Cap 7,262,600 USD
- Current Price $ 3.17
- High / Low $ 3.25 / 2.78
- Stock P/E N/A
- Book Value 3.23
- EPS -1.34
- Next Earning Report 2026-08-11
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.22 %
- ROE -0.37 %
- 52 Week High 13.93
- 52 Week Low 1.90
About
Xenetic Biosciences, Inc., a biopharmaceutical company, is focused on advancing XCART, a customized chimeric antigen receptor T (CAR T) platform technology designed to target patient-specific tumor neoantigens. The company is headquartered in Framingham, Massachusetts.
Analyst Target Price
$40.00
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-11 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: XBIO
2026-08-07 22:40:11
Xenetic Biosciences reported its Q2 2026 financial results, showing approximately $0.7 million in royalty revenue and a net loss of $0.9 million. The company ended the quarter with $6.5 million in cash and highlighted expanded translational research and collaborations for its DNase platform. Business advancements include positive preclinical data presentations and partner approvals for an exploratory study.
2026-08-07 22:40:11
Xenetic Biosciences announced its second-quarter 2026 financial results, emphasizing continued progress with its proprietary DNase platform. The company reported a 12% increase in royalty revenue due to a sublicense agreement with Takeda Pharmaceuticals, while R&D expenses decreased and G&A expenses rose due to legal costs for strategic review. Xenetic highlighted positive preclinical data for DNase I in enhancing CAR T-cell therapies and a new collaboration for an investigator-initiated study in large B-cell lymphoma.
2026-08-07 22:40:11
Xenetic Biosciences reported its Q2 2026 financial results, highlighting approximately $0.7 million in royalty revenue and a net loss of $0.9 million. The company announced that its collaboration partner, PeriNess Ltd., received Israeli regulatory approvals to conduct an exploratory study of DNase I in combination with CAR T-cell therapy for large B-cell lymphoma. Xenetic continues to advance its proprietary DNase platform, focusing on enhancing existing cancer therapies by targeting neutrophil extracellular traps.
2026-08-06 22:40:11
Xenetic Biosciences, Inc. (XBIO) reported its 2026 quarterly results with revenue of $660.6K, a 12% increase year-over-year, and a diluted loss per share of ($0.41). The company's net loss was ($929.7K), an increase of 35% from the prior year quarter. Revenue growth was primarily driven by royalty income from a Takeda sublicense, while R&D spending decreased.
2026-07-30 18:39:31
This article provides a valuation analysis of Xenetic Biosciences Inc (XBIO) as of July 30, 2026. The company currently holds a valuation score of 8.31, ranking 140 out of 384 in its industry, with a P/E ratio of -2.14. The article notes that relevant data for P/B, P/S, and P/CF ratios have not yet been disclosed by the company.
2026-07-30 06:09:46
Xenetic Biosciences Inc (XBIO) currently holds an institutional shareholding score of 3.00, placing it 191st out of 384 in the Biotechnology & Medical Research industry. The institutional shareholding proportion has decreased by 53.00% quarter-over-quarter, now standing at 4.97%. James Simons is identified as the largest institutional shareholder, though detailed shareholding information is also provided for other institutions like Renaissance Technologies LLC and The Vanguard Group, Inc.
